Search results
Results from the WOW.Com Content Network
The fluorescein is administered intravenously in intravenous fluorescein angiography (IVFA) and orally in oral fluorescein angiography (OFA). The test is a dye tracing method. The fluorescein dye also reappears in the patient urine, causing the urine to appear darker, and sometimes orange. [2] It can also cause discolouration of the saliva.
Fluorescein drops being instilled for an eye examination. Intravenous or oral fluorescein is used in fluorescein angiography in research and to diagnose and categorize vascular disorders including retinal disease, macular degeneration, diabetic retinopathy, inflammatory intraocular conditions, and intraocular tumors.
Angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers.
Fluorescein is a dye which is taken up by damaged cornea such that the area appears green under cobalt blue light. [3] There is also a version that comes premixed with lidocaine. [4] [8] Fluorescein was first made in 1871. [9] It is on the World Health Organization's List of Essential Medicines. [10]
While conventional dye-based angiography is still the common gold standard, OCTA has been evaluated and used across many diseases. [4] [5] [25] OCTA was first introduced in clinical eyecare in 2014. [26] OCTA has applications in several diseases, including leading causes of blindness such as glaucoma [24] and age-related macular degeneration. [27]
Angiography is a process of photographing/recording vascular flow within the retina and surrounding tissue by injecting a fluorescent dye into the blood stream. This dye fluoresces a different colour when light from a specific wavelength (excitation colour) reaches it.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The first version of the LEA test was developed in 1976 by Finnish pediatric ophthalmologist Lea Hyvärinen, MD, PhD. Dr. Hyvärinen completed her thesis on fluorescein angiography and helped start the first clinical laboratory in that area while serving as a fellow at the Wilmer Eye Institute of Johns Hopkins Hospital in 1967.